Delerive, Philippe

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry

Peroxisome Proliferator-Activated ReceptorsCytokine Signaling Pathways and Interactions

Cited by 1,089

Peroxisome proliferator-activated receptors in inflammation control

Delerive, P., Fruchart, J., & Staels, B. (2001) · Journal of Endocrinology

Peroxisome Proliferator-Activated ReceptorsFatty Acid Research and Health

Cited by 755

A Paradigm for Gene Regulation: Inflammation, NF-κB and PPAR

Vanden Berghe, W., Vermeulen, L., Delerive, P., De Bosscher, K., Staels, B., & Haegeman, G. (2003) · Advances in experimental medicine and biology

NF-κB Signaling PathwaysGenomics and Chromatin Dynamics

Cited by 222

Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-γ, Inhibits the Jun NH2-Terminal Kinase/Activating Protein 1 Pathway and Protects the Heart From Ischemia/Reperfusion Injury

Khandoudi, N., Delerive, P., Berrebi-Bertrand, I., Buckingham, R. E., Staels, B., & Bril, A. (2002) · Diabetes

Cardiac Ischemia and ReperfusionPeroxisome Proliferator-Activated Receptors

Cited by 174

G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus

Riddy, D. M., Delerive, P., Summers, R. J., Sexton, P. M., & Langmead, C. J. (2018) · Pharmacological Reviews

Receptor Mechanisms and SignalingDiabetes Treatment and Management

Cited by 108